GLIMEPIRIDE-WGR

What it is

Glimepiride-WGR tablets are available in four strengths: 1 mg, 2 mg, 3 mg and 4 mg. Glimepiride is a sulfonylurea anti-diabetic agent which decreases blood glucose concentrations. The primary mechanism of action of glimepiride appears to be dependent on stimulating the release of insulin from functioning pancreatic beta cells. Glimepiride acts in concert with glucose by improving the sensitivity of beta cells to physiological glucose stimulus, resulting in insulin secretion in the rhythm of meals.

Approved indications

— As an adjunct to diet, exercise and weight loss, to lower the blood glucose in patients with non-insulin-dependent (type 2) diabetes mellitus.

Dosing overview

The initial dose of glimepiride is one 1 mg tablet once daily. The tablet should be swallowed whole with adequate liquid (for example, half a glass of water) immediately before breakfast. If metabolic control is unsatisfactory after 1 to 2 weeks of treatment, increase the daily dose in increments of 1 mg at 1 to 2 week intervals, until satisfactory metabolic control is achieved. Most patients will achieve optimum control at doses of 1 mg to 4 mg once daily. Only in exceptional cases will doses of more than 4 mg glimepiride per day give better results.

Key safety warnings

Hypoglycaemia is a potential risk from treatment with any sulfonylurea, particularly in the first month of treatment or when dosage is increased. Debilitated patients, malnourished patients and patients with adrenal, pituitary, renal or hepatic insufficiency are particularly susceptible to the hypoglycaemic action of sulfonylureas and should therefore be carefully monitored. The dosage of glimepiride should be carefully adjusted in these patients. Alcohol ingestion, severe or prolonged exercise, deficient caloric intake or use of more than one antidiabetic agent may predispose patients to the development of hypoglycaemia. Treatment of patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency with sulfonylurea agents can lead to haemolytic anaemia. Since glimepiride belongs to the class of sulfonylurea agents, caution should be used in patients with G6PD-deficiency and a non-sulfonylurea alternative should be considered. Alertness and reactions may be impaired due to hypo- or hyperglycaemia, especially when beginning or after altering treatment or when Glimepiride-WGR is not taken regularly. This may, for example, affect the ability to drive or to operate machinery.

Contraindications

Hypersensitivity to glimepiride, other sulfonylureas, other sulfonamides or any excipient. Severe impairment of renal function (CrCl < 30 mL/min). Dialysis patients. Severe hepatic dysfunction. Pregnancy. Lactation. Not suitable for the treatment of insulin-dependent (type 1) diabetes mellitus (for example, for the treatment of patients with a history of ketoacidosis), nor for the treatment of diabetic ketoacidosis, nor for the treatment of diabetic precoma or coma.

Regulatory history

Glimepiride-WGR tablets in 1 mg, 2 mg, 3 mg and 4 mg strengths were first listed on the ARTG on 17 March 2017.